MX378664B - Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. - Google Patents
Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.Info
- Publication number
- MX378664B MX378664B MX2016010071A MX2016010071A MX378664B MX 378664 B MX378664 B MX 378664B MX 2016010071 A MX2016010071 A MX 2016010071A MX 2016010071 A MX2016010071 A MX 2016010071A MX 378664 B MX378664 B MX 378664B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- vmat2
- inhibitor
- monomin
- vesicular
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000022610 schizoaffective disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937223P | 2014-02-07 | 2014-02-07 | |
| PCT/US2015/014893 WO2015120317A1 (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010071A MX2016010071A (es) | 2017-04-27 |
| MX378664B true MX378664B (es) | 2025-03-10 |
Family
ID=52589782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010071A MX378664B (es) | 2014-02-07 | 2015-02-06 | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9782398B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4049681B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6718376B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102328058B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113413385A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015213778B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2938581C (cg-RX-API-DMAC7.html) |
| IL (1) | IL247127B (cg-RX-API-DMAC7.html) |
| MX (1) | MX378664B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ760790A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2021128797A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015120317A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6635945B2 (ja) * | 2014-05-06 | 2020-01-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| RU2736509C2 (ru) | 2015-02-06 | 2020-11-17 | Ньюрокрайн Байосайенсиз, Инк. | [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы |
| JP7109360B2 (ja) | 2015-10-30 | 2022-07-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | バルベナジン塩およびその多形体 |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| CN109153676B (zh) * | 2016-06-29 | 2021-08-10 | 苏州科睿思制药有限公司 | Nbi-98854的晶型及其制备方法和用途 |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| EA201991782A1 (ru) | 2017-01-27 | 2021-09-23 | Нейрокрин Байосайенсиз, Инк. | Способы введения некоторых vmat2-ингибиторов |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| CN111372567B (zh) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 |
| WO2019074492A1 (en) | 2017-10-10 | 2019-04-18 | Obrien Christopher F | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019129100A1 (zh) | 2017-12-26 | 2019-07-04 | 苏州科睿思制药有限公司 | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 |
| US12144899B2 (en) | 2018-04-25 | 2024-11-19 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| US20210236482A1 (en) * | 2018-05-04 | 2021-08-05 | Korea Institute Of Radiological & Medical Sciences | Radiation sensitivity enhancing composition containing aripiprazole as active ingredient |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| IL320987A (en) | 2018-08-15 | 2025-07-01 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020188551A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for treating autism spectrum disorder and associated disorders |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| MX2023014827A (es) * | 2021-06-30 | 2024-01-15 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| AU1321900A (en) * | 1998-10-23 | 2000-05-15 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| US20110257220A1 (en) * | 2005-08-06 | 2011-10-20 | Cambridge Laboratories (Ireland) Limited | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses |
| PT2081929E (pt) * | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| NO3061760T3 (cg-RX-API-DMAC7.html) * | 2008-09-18 | 2018-04-07 | ||
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2015
- 2015-02-06 RU RU2021128797A patent/RU2021128797A/ru unknown
- 2015-02-06 EP EP21216409.9A patent/EP4049681B1/en active Active
- 2015-02-06 AU AU2015213778A patent/AU2015213778B2/en active Active
- 2015-02-06 WO PCT/US2015/014893 patent/WO2015120317A1/en not_active Ceased
- 2015-02-06 KR KR1020167024297A patent/KR102328058B1/ko active Active
- 2015-02-06 NZ NZ760790A patent/NZ760790A/en unknown
- 2015-02-06 CN CN202110257547.XA patent/CN113413385A/zh active Pending
- 2015-02-06 CN CN201580009498.0A patent/CN106061506A/zh active Pending
- 2015-02-06 CA CA2938581A patent/CA2938581C/en active Active
- 2015-02-06 MX MX2016010071A patent/MX378664B/es unknown
- 2015-02-06 EP EP15706596.2A patent/EP3102239A1/en not_active Withdrawn
- 2015-02-06 US US15/116,786 patent/US9782398B2/en active Active
- 2015-02-06 CN CN202110257206.2A patent/CN113368110A/zh active Pending
- 2015-02-06 NZ NZ723107A patent/NZ723107A/en unknown
- 2015-02-06 RU RU2016135930A patent/RU2757221C2/ru active
- 2015-02-06 JP JP2016549493A patent/JP6718376B2/ja active Active
-
2016
- 2016-08-04 IL IL247127A patent/IL247127B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/701,311 patent/US20180085364A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/248,855 patent/US20190381029A1/en not_active Abandoned
- 2019-05-07 JP JP2019087459A patent/JP2019116515A/ja not_active Withdrawn
-
2020
- 2020-03-13 US US16/817,723 patent/US20200206215A1/en not_active Abandoned
-
2021
- 2021-03-02 JP JP2021032320A patent/JP2021080294A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195803A patent/JP2024003253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015120317A1 (en) | 2015-08-13 |
| KR102328058B1 (ko) | 2021-11-17 |
| CN113368110A (zh) | 2021-09-10 |
| CA2938581C (en) | 2023-02-28 |
| JP6718376B2 (ja) | 2020-07-08 |
| NZ723107A (en) | 2022-11-25 |
| RU2757221C2 (ru) | 2021-10-12 |
| RU2021128797A (ru) | 2021-11-26 |
| CN113413385A (zh) | 2021-09-21 |
| AU2015213778A1 (en) | 2016-08-18 |
| JP2024003253A (ja) | 2024-01-11 |
| US20160339011A1 (en) | 2016-11-24 |
| RU2016135930A3 (cg-RX-API-DMAC7.html) | 2018-10-05 |
| JP2021080294A (ja) | 2021-05-27 |
| US20190381029A1 (en) | 2019-12-19 |
| KR20160132830A (ko) | 2016-11-21 |
| JP2017505316A (ja) | 2017-02-16 |
| US20200206215A1 (en) | 2020-07-02 |
| EP4049681B1 (en) | 2026-01-07 |
| AU2015213778B2 (en) | 2020-04-23 |
| US20180085364A1 (en) | 2018-03-29 |
| RU2016135930A (ru) | 2018-03-15 |
| CA2938581A1 (en) | 2015-08-13 |
| CN106061506A (zh) | 2016-10-26 |
| NZ760790A (en) | 2022-11-25 |
| EP3102239A1 (en) | 2016-12-14 |
| IL247127B (en) | 2021-04-29 |
| US9782398B2 (en) | 2017-10-10 |
| IL247127A0 (en) | 2016-09-29 |
| JP2019116515A (ja) | 2019-07-18 |
| EP4049681A1 (en) | 2022-08-31 |
| MX2016010071A (es) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378664B (es) | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. | |
| ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| ECSP17039611A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| CL2015000706A1 (es) | Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos. | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| MX380239B (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona. | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| CR20140405A (es) | Apoptosis señal reguladores del inhibidor de quinasa | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| CO2018003473A2 (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |